.png){kind=logo}
How Retatrutide Works — The Triple Receptor Mechanism Explained
- Rob Lagana
- May 28
- 5 min read
In May 2026, Eli Lilly reported the pivotal Phase 3 TRIUMPH-1 trial results for retatrutide. Average body weight loss of 28.3 percent at 80 weeks. Up to 30.3 percent at 104 weeks in a prespecified extension. The largest weight loss numbers ever recorded in a Phase 3 randomized controlled trial of any compound in this class.
The question everyone is asking is a reasonable one: how does a single weekly injection produce results that rival bariatric surgery?
The answer is in the receptor mechanism. And understanding it changes how you think about the entire GLP-1 class of compounds.
How Retatrutide Works — The Receptor Progression
Every compound in the GLP-1 class works by activating hormone receptors — protein structures embedded in cell membranes that receive chemical signals and trigger biological responses. Think of each receptor as a lock. The drug is the key. When the key turns the lock, the cell receives a signal to change its behavior.
The progression from semaglutide to tirzepatide to retatrutide is a progression of how many locks open simultaneously.
Semaglutide — sold as Wegovy for weight management — activates one receptor: the GLP-1 receptor. In the STEP-1 trial published in the New England Journal of Medicine, semaglutide produced approximately 15 percent average body weight loss at 68 weeks.
Tirzepatide — sold as Zepbound — activates two receptors: GLP-1 and GIP. In the SURMOUNT-1 trial, tirzepatide produced 22.5 percent average body weight loss at 72 weeks. More receptors, more metabolic pathways activated, greater results.
Retatrutide activates three receptors simultaneously: GLP-1, GIP, and glucagon. That third receptor — the glucagon receptor — is the differentiator. It is what separates retatrutide from everything that came before it.
What Each Receptor Actually Does
Understanding how retatrutide works requires understanding what each of its three receptor pathways actually produces.
The GLP-1 receptor drives appetite reduction, slows gastric emptying so food moves through the stomach more slowly and satiety lasts longer, and improves insulin sensitivity. This is the foundation of the entire compound class.
The GIP receptor enhances insulin secretion, may improve lipid metabolism, and stimulates lipolysis — the direct breakdown of fat in adipose tissue. Adding GIP to GLP-1 is why tirzepatide consistently outperforms semaglutide. It opens a second metabolic door that semaglutide never accesses.
The glucagon receptor is what makes retatrutide's results categorically different. When the glucagon receptor is activated, energy expenditure increases — meaning the body burns more calories at rest. Hepatic fatty acid oxidation increases — meaning the liver actively burns fat rather than storing it. Liver fat accumulation is reduced directly. And lipolysis is further stimulated on top of the GIP contribution.
In plain language: semaglutide reduces how much you eat. Retatrutide reduces how much you eat and simultaneously increases how much you burn. That dual mechanism is why the Phase 3 numbers look the way they do.
What the Phase 3 Data Actually Shows
The TRIUMPH-1 trial enrolled 2,339 adults with obesity or overweight and at least one weight-related comorbidity, with no type 2 diabetes, across 13 countries including Canada. Mean baseline weight was 248.5 pounds.
At the 12 milligram dose at 80 weeks: 28.3 percent average body weight loss. 70.3 pounds lost on average. 45.3 percent of participants lost more than 30 percent of their body weight — bariatric surgery territory. 65.3 percent reached a BMI below 30.
In a prespecified 104-week extension among participants with baseline BMI of 35 or above who tolerated their assigned dose: average weight loss of 30.3 percent — 85 pounds. No plateau was observed at that point.
Secondary findings included significant improvements in waist circumference, non-HDL cholesterol, triglycerides, systolic blood pressure, and high-sensitivity CRP.
This follows the earlier TRIUMPH-4 trial reported in December 2025, which showed 28.7 percent weight loss at 68 weeks in adults with obesity and knee osteoarthritis, along with a 75.8 percent reduction in osteoarthritis pain scores.
An important note on these numbers: as of May 2026, all Phase 3 data comes from Eli Lilly press releases. Full peer-reviewed publications are expected following the American Diabetes Association Scientific Sessions in New Orleans in June 2026. The mechanism data referenced in this post is drawn from the Phase 2 trial published in the New England Journal of Medicine in 2023.
On the Side Effect Profile
Understanding how retatrutide works also means understanding its complete profile — including adverse effects.
GI effects — nausea, diarrhea, vomiting — were consistent with the GLP-1 class and concentrated during the titration phase. Dysesthesia, an abnormal skin sensation described as tingling or tenderness and believed to be related to glucagon receptor activation, occurred in approximately 12.5 percent of participants at the 12 milligram dose compared to 0.9 percent on placebo. Most cases were mild and resolved on treatment.
AE-related discontinuations at the 12 milligram dose were 11.3 percent compared to 4.9 percent on placebo. Notably, the 4 milligram dose — reached after a single titration step — produced 19 percent weight loss with a discontinuation rate lower than placebo.
These are the numbers that matter for anyone over 40 evaluating this compound. The results are extraordinary. The foundation you bring to the compound — your recovery capacity, sleep architecture, hormonal environment, and resistance training program — determines whether you are in the group that achieves those results or the group that discontinues due to adverse events.
Why This Matters Specifically for Adults Over 40
The glucagon receptor activation in retatrutide addresses something that no previous GLP-1 compound targeted: energy expenditure at rest. This is directly relevant for adults over 40.
Research published in JAMA found that more than 25 percent of men between 40 and 70 have clinically low testosterone. Testosterone decline is directly associated with reduced resting energy expenditure, increased visceral fat, and insulin resistance. The glucagon receptor pathway addresses the energy expenditure side of that equation — the side that testosterone decline suppresses.
For women, the parallel shift occurs through declining estrogen and progesterone, both of which affect metabolic rate, fat distribution, and insulin sensitivity. The triple receptor mechanism addresses multiple aspects of that hormonal shift simultaneously.
The compound is not a program. The research consistently shows that GLP-1 class compounds produce optimal results when built on a foundation of structured resistance training, adequate protein intake, optimized sleep, and hormonal support. Without that foundation, significant weight loss can occur — but a meaningful proportion of that loss will come from lean muscle mass rather than fat.
Understanding how retatrutide works is the starting point. Understanding how to build the program around it is what determines the outcome.
If you want to understand that framework in detail — the Protocol Briefing is the right place to start.
Access the Protocol Briefing here → powerskulpt.myflodesk.com/protocol-briefing
If you are currently on a GLP-1 compound and not getting the results you expected, the Retatrutide Troubleshooter walks through the most common reasons results stall and what to address first.
Retatrutide Troubleshooter → powerskulpt.com/retatrutide-troubleshooter
If you are ready to work directly with a coach who has applied this methodology for 33 years — the Advanced Consultation is the right next step.
Book a 60-minute Advanced Consultation → calendly.com/powerskulpt-assessment/powerskulpt-consultation] ($300 CAD
"Training creates the signal. Recovery creates the change." — Rob Lagana, Co-founder, PowerSkulpt
"Most programs start with training. PowerSkulpt starts with recovery."
Scientific References
Jastreboff, A.M. et al. (2023). Triple Hormone Receptor Agonist Retatrutide for Obesity — Phase 2. NEJM, 389:514–526. https://doi.org/10.1056/NEJMoa2301972
Wilding, J.P.H. et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. NEJM, 384:989–1002.
Jastreboff, A.M. et al. (2022). Tirzepatide SURMOUNT-1. NEJM, 387:205–216.
Eli Lilly. TRIUMPH-1 Phase 3 topline results. May 21, 2026. investor.lilly.com
Eli Lilly. TRIUMPH-4 Phase 3 topline results. December 11, 2025. investor.lilly.com
Pencina, K.M. et al. (2023). JAMA Network Open, 6(10).